Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 12/16/2020 (updated 4/4/2024)
As states seek new tools to meet the needs of individuals with substance use disorder (SUD) and opioid use disorder, federally qualified health centers (FQHCs) offer unique resources and examples for developing integrated and cost-effective health care services for complex and chronic conditions. The National Academy for State Health Policy developed this toolkit to share innovations, resources, and lessons learned from five state teams (AL, IL, SD, VA, and WI) that are working to strengthen the capacity of their FQHCs to deliver SUD care
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 6/26/2020 (updated 3/28/2024)
The MAT for OUD Playbook aims to address the growing need for guidance as more primary care practices and health systems begin to implement MAT. The Playbook’s framework is designed to be useful for practices implementing any array of MAT services.
Posted 7/24/2020 (updated 3/28/2024)
This final rule makes changes to the Department of Health and Human Services’ (HHS) regulations governing the Confidentiality of Substance Use Disorder Patient Records. These changes were prompted by the need to continue aligning the regulations with advances in the U.S. health care delivery system, while retaining important privacy protections for individuals seeking treatment for substance use disorders (SUDs).